The effect of imatinib on cytomegalovirus reactivation in hematopoietic cell transplantation.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 19886798.
- Also identified by DOI 10.1086/648120 and PMC identifier 2779734.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In vitro studies have shown possible antiviral effects of tyrosine kinase inhibitors. In a retrospective study, we show that use of the tyrosine kinase inhibitor imatinib does not appear to reduce cytomegalovirus reactivation during the first 100 days after transplantation in a cohort of hematopoietic cell transplant recipients.
Medical subject headings
- Antiviral Agents
- Cytomegalovirus
- Cytomegalovirus Infections
- Hematopoietic Stem Cell Transplantation
- Piperazines
- Pyrimidines
- Virus Activation